HYFT
ImmunoPrecise Antibodies Ltd.
1.50$
-3.2%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +4.1% | -23.8% | -1.0% | +1.1% | -24.1% | -2.4% | -8.3% | -35.9% | -34.6% | +25.1% | -18.8% | |
| – | -2.3% | -23.7% | -4.1% | +13.5% | +65.9% | -9.6% | +93.3% | -40.0% | -35.8% | +16.1% | -24.5% | |
| – | +3.1% | -44.2% | +13.1% | -9.7% | +265.4% | -17.4% | -54.1% | +237.1% | -37.1% | +9.0% | -32.7% | |
| – | +3.1% | -44.2% | +13.1% | -9.7% | +265.4% | -17.4% | +204.1% | -49.1% | -37.1% | +9.0% | -32.7% | |
| – | -4.4% | -9.1% | -13.5% | +50.8% | -8.3% | -1.2% | -45.9% | +61.3% | -45.8% | +57.3% | -10.0% | |
| – | +3.3% | -15.5% | -12.6% | +7.5% | -4.5% | +9.1% | -75.0% | +1.3% | -31.9% | +35.7% | +24.4% | |
| – | -1.4% | -58.8% | +2.1% | +0.9% | -0.6% | +4.6% | -100.0% | – | – | – | – | |
| – | -3.8% | -15.4% | -0.6% | -1.8% | -95.1% | -5.1% | – | – | – | – | – | |
| – | +22.5% | -9.7% | +1.5% | +3.2% | -25.2% | +2.0% | -3.9% | -58.0% | -27.5% | +57.8% | +8.4% | |
| – | +20.6% | -10.6% | +37.5% | +11.1% | -28.0% | +0.9% | +85.2% | -68.9% | -26.7% | +52.0% | +15.0% | |
| – | +224.0% | -12.6% | +55.7% | +13.1% | -64.5% | +9.5% | -77.7% | +74.7% | -56.3% | +44.7% | +5.9% | |
| – | +10.0% | +17.9% | +36.9% | +11.8% | -18.4% | +20.3% | -38.0% | +4.8% | -28.3% | +69.4% | +30.5% | |
| – | -4.3% | -31.9% | -3.1% | -0.5% | -23.1% | -6.0% | -12.2% | -14.6% | -38.0% | +6.9% | -41.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +3.0% | +4.4% | +0.7% | +3.7% | +16.8% | +0.8% | +19.7% | +16.4% | +0.8% | +0.4% | +0.2% |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.